Title:
NON-ANTAGONISTIC EGFR-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF
Document Type and Number:
WIPO Patent Application WO/2012/058592
Kind Code:
A3
Abstract:
The disclosure provides anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR. Specifically, the disclosure provides anti-EGFR antibodies and fragments thereof which do not inhibit EGFR signaling but are highly cytotoxic to EGFR overexpressing tumor cells. The methods of using the agents, antibodies, or immunoconjugates, for inhibiting tumor growth are also provided.
Inventors:
SETIADY JULIANTO (US)
SINGH RAJEEVA (US)
PARK PETER U (US)
RUI LINGYUN (US)
CHITTENDEN THOMAS (US)
SINGH RAJEEVA (US)
PARK PETER U (US)
RUI LINGYUN (US)
CHITTENDEN THOMAS (US)
Application Number:
PCT/US2011/058385
Publication Date:
August 16, 2012
Filing Date:
October 28, 2011
Export Citation:
Assignee:
IMMUNOGEN INC (US)
SETIADY JULIANTO (US)
SINGH RAJEEVA (US)
PARK PETER U (US)
RUI LINGYUN (US)
CHITTENDEN THOMAS (US)
SETIADY JULIANTO (US)
SINGH RAJEEVA (US)
PARK PETER U (US)
RUI LINGYUN (US)
CHITTENDEN THOMAS (US)
International Classes:
A61K39/00; C07K16/00; A61K39/395; C12N5/02; C12N5/16; C12N15/00
Domestic Patent References:
| WO2010055950A1 | 2010-05-20 | |||
| WO2008098145A1 | 2008-08-14 |
Foreign References:
| US20100008929A1 | 2010-01-14 | |||
| US20040031072A1 | 2004-02-12 | |||
| EP1033406A1 | 2000-09-06 | |||
| US20090175881A1 | 2009-07-09 | |||
| US20070141048A1 | 2007-06-21 | |||
| US20100190247A1 | 2010-07-29 | |||
| US20040259942A1 | 2004-12-23 | |||
| US20090022677A1 | 2009-01-22 | |||
| US20090258442A1 | 2009-10-15 | |||
| US20110287036A1 | 2011-11-24 |
Other References:
YANG ET AL.: "Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant Chemotherapy.", CANCER RES., vol. 59, no. 6, 1999, pages 1236 - 1243, XP008154927
DATABASE UNIPROTKB [online] UNIPROT; 23 September 2008 (2008-09-23), XP003030127, Database accession no. B4NGM2
MODJTAHEDI ET AL.: "Anti-EGFR monoclonal antibodies which act as EGF, TGF alpha, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours.", INT J CANCER., vol. 75, no. 2, 1998, pages 310 - 6, XP002492891
JOST ET AL.: "Matrix-independent Survival of Human Keratinocytes through an EGF Receptor/MAPK-Kinase-dependent Pathway.", MOL BIOL CELL., vol. 12, no. 5, 2001, pages 1519 - 27, XP055107131
KIM ET AL.: "E-cadherin promotes EGFR-mediated cell differentiation and MUC5AC mucin expression in cultured human airway epithelial cells.", AM J PHYSIOL LUNG CELL MOL PHYSIOL., vol. 289, no. 6, 2005, pages L1061 - 1074, XP055107137
FRIESS ET AL.: "CombinationTreatment with Erlotinib and Pertuzumab against HumanTumor Xenografts Is Superior to Monotherapy.", CLIN CANCER RES., vol. 11, no. 14, 2005, pages 5300 - 9, XP002393212
LAMMERTS VAN BUEREN ET AL.: "The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.", PROC NATL ACAD SCI USA., vol. 105, no. 16, 2008, pages 6109 - 6114, XP055107140
KAMAT ET AL.: "Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425.", CANCER BIOL THER., vol. 7, no. 5, 2008, pages 726 - 33, XP055107143
DATABASE UNIPROTKB [online] UNIPROT; 23 September 2008 (2008-09-23), XP003030127, Database accession no. B4NGM2
MODJTAHEDI ET AL.: "Anti-EGFR monoclonal antibodies which act as EGF, TGF alpha, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours.", INT J CANCER., vol. 75, no. 2, 1998, pages 310 - 6, XP002492891
JOST ET AL.: "Matrix-independent Survival of Human Keratinocytes through an EGF Receptor/MAPK-Kinase-dependent Pathway.", MOL BIOL CELL., vol. 12, no. 5, 2001, pages 1519 - 27, XP055107131
KIM ET AL.: "E-cadherin promotes EGFR-mediated cell differentiation and MUC5AC mucin expression in cultured human airway epithelial cells.", AM J PHYSIOL LUNG CELL MOL PHYSIOL., vol. 289, no. 6, 2005, pages L1061 - 1074, XP055107137
FRIESS ET AL.: "CombinationTreatment with Erlotinib and Pertuzumab against HumanTumor Xenografts Is Superior to Monotherapy.", CLIN CANCER RES., vol. 11, no. 14, 2005, pages 5300 - 9, XP002393212
LAMMERTS VAN BUEREN ET AL.: "The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.", PROC NATL ACAD SCI USA., vol. 105, no. 16, 2008, pages 6109 - 6114, XP055107140
KAMAT ET AL.: "Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425.", CANCER BIOL THER., vol. 7, no. 5, 2008, pages 726 - 33, XP055107143
Attorney, Agent or Firm:
STERNE, Robert, Greene et al. (P.L.L.C.1100 New York Avenue, N, Washington DC, US)
Download PDF:
Previous Patent: BIOMATERIAL COMPOSITIONS
Next Patent: PRINTER WITH PRINTHEAD ASSEMBLY, CLUTCH ASSEMBLY, AND PRINTER RIBBON TRANSPORT ASSEMBLY
Next Patent: PRINTER WITH PRINTHEAD ASSEMBLY, CLUTCH ASSEMBLY, AND PRINTER RIBBON TRANSPORT ASSEMBLY